Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats

Heather N Tinsley; Bini Mathew; Xi Chen; Yulia Y Maxuitenko; Nan Li; Whitney M Lowe; Jason D Whitt; Wei Zhang; Bernard D Gary; Adam B Keeton; William E Grizzle; Clinton J Grubbs; Robert C Reynolds; Gary A Piazza

doi:10.3390/cancers15030646

Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats

Cancers (Basel). 2023 Jan 20;15(3):646. doi: 10.3390/cancers15030646.

Authors

Affiliations

¹ Department of Biology Chemistry, Mathematics, and Computer Science, University of Montevallo, Montevallo, AL 35115, USA.
² Drug Discovery Division, Southern Research, Birmingham, AL 35205, USA.
³ Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
⁴ Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
⁵ Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
⁶ Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
⁷ O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35205, USA.

Abstract

The nonsteroidal anti-inflammatory drug (NSAID) sulindac demonstrates attractive anticancer activity, but the toxicity resulting from cyclooxygenase (COX) inhibition and the suppression of physiologically important prostaglandins precludes its long-term, high dose use in the clinic for cancer prevention or treatment. While inflammation is a known tumorigenic driver, evidence suggests that sulindac's antineoplastic activity is partially or fully independent of its COX inhibitory activity. One COX-independent target proposed for sulindac is cyclic guanosine monophosphate phosphodiesterase (cGMP PDE) isozymes. Sulindac metabolites, i.e., sulfide and sulfone, inhibit cGMP PDE enzymatic activity at concentrations comparable with those associated with cancer cell growth inhibitory activity. Additionally, the cGMP PDE isozymes PDE5 and PDE10 are overexpressed during the early stages of carcinogenesis and appear essential for cancer cell proliferation and survival based on gene silencing experiments. Here, we describe a novel amide derivative of sulindac, sulindac sulfide amide (SSA), which was rationally designed to eliminate COX-inhibitory activity while enhancing cGMP PDE inhibitory activity. SSA was 68-fold and 10-fold less potent than sulindac sulfide (SS) in inhibiting COX-1 and COX-2, respectively, but 10-fold more potent in inhibiting growth and inducing apoptosis in breast cancer cells. The pro-apoptotic activity of SSA was associated with inhibition of cGMP PDE activity, elevation of intracellular cGMP levels, and activation of cGMP-dependent protein kinase (PKG) signaling, as well as the inhibition of β-catenin/Tcf transcriptional activity. SSA displayed promising in vivo anticancer activity, resulting in a 57% reduction in the incidence and a 62% reduction in the multiplicity of tumors in the N-methyl-N-nitrosourea (MNU)-induced model of breast carcinogenesis. These findings provide strong evidence for cGMP/PKG signaling as a target for breast cancer prevention or treatment and the COX-independent anticancer properties of sulindac. Furthermore, this study validates the approach of optimizing off-target effects by reducing the COX-inhibitory activity of sulindac for future targeted drug discovery efforts to enhance both safety and efficacy.

Keywords: breast cancer; cyclic guanosine monophosphate (cGMP); cyclooxygenase (COX); nonsteroidal anti-inflammatory drug (NSAID); phosphodiesterase (PDE); sulindac.

Abstract

Grants and funding